Hepatocellular Carcinoma
Conditions
Brief summary
Liver cancer is the fifth most common cancer and the second most frequent cause of cancer-related death globally. Hepatocellular carcinoma represents about 90% of primary liver cancers and constitutes a major global health problem. The pattern of HCC occurrence shows a significant geographical imbalance, with the highest incidence rates in East Asia (more than 50% of the cases occurring in China). The aim of this study is to investigate the overall survival (OS) of patients diagnosed with unresectable hepatocellular carcinoma under real-world practice conditions in Asia Pacific region.
Interventions
None listed
Sponsors
Tokyo University
Humanity & Health Medical Group Limited
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with a diagnosis of unresectable hepatocellular carcinoma * Able to comprehend and provide written informed consent in accordance with institutional guidelines.
Exclusion criteria
* Patients not willing to participate and/or give their written informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall survival | Up to 5 years | Overall survival (OS) is defined as the time (days) from the date of unresectable HCC diagnosis to the date of death, due to any reason. Patients alive or lost to follow-up at the time of analysis will be censored at their last date of follow-up |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | Up to 5 years | Progression-free survival (PFS) is defined as the time (days) from the start of treatment to the date of first observed disease progression (radiological or clinical, whichever is earlier) or death due to any cause, if death occurs before progression is documented |
| Time to progression (TTP) | Up to 5 years | Time to progression (TTP) is defined as the time (days) from the start of treatment to the first documented disease progression |
| Duration of treatment | Up to 5 years | Duration of treatment, defined by the time interval from the start of treatment to the day of permanent discontinuation of treatment (including death) |
| Frequency and Severity of Adverse Events | Up to 5 years | Safety will be evaluated by monitoring and recording the grade 3, 4 and 5 adverse events (AE) occurring during and after treatment throughout follow up of patients. |
Countries
China, Hong Kong, Japan
Contacts
Primary ContactDanny Wang, PhD
Outcome results
None listed